Anteris Technologies Global Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Wayne Geoffrey Paterson
- Full Time Employees
- 174
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 860 Blue Gentian Road, Suite 340 Eagan MN United States 55121
- IPO Date
- Dec 13, 2024
- CIK
- 0002011514
- Website
- anteristech.com
- Similar Companies
- Business
- Anteris Technologies Global Corp. operates as a structural heart company, dedicating its efforts to the discovery, advancement, and commercialization of innovative medical devices aimed at enhancing patient well-being, particularly for those with aortic stenosis. The company's primary innovation is the DurAVR transcatheter heart valve system, a pioneering single-piece, biomimetic transcatheter aortic valve. This valve is specifically engineered to replicate the form and function of a healthy native aortic valve, promoting natural, laminar blood flow. Complementing its flagship valve, the firm develops ADAPT anti-calcification tissue, a proprietary bovine pericardial tissue engineering process. This advanced preparation transforms xenograft tissue into robust bioscaffolds that exhibit long-term durability and have been clinically demonstrated to remain free of calcification for up to a decade, finding widespread use in various surgical repair applications, including cardiac and vascular patches. Furthermore, Anteris provides the ComASUR delivery system, a specialized balloon-expandable platform co-developed with physicians. This system incorporates a reinforced, steerable catheter, enabling highly precise and controlled delivery of the DurAVR valve within the intricate heart anatomy, minimizing potential damage. Anteris Technologies Global Corp. was founded in 1999 and is headquartered in Toowong, Australia, with a significant operational presence in Minneapolis, USA. The company recently completed a U.S. initial public offering, dual-listing, and re-domiciliation to the United States in late 2024 to support the continued development and commercialization of its product pipeline, including advancing its PARADIGM Trial.
Company News
Anteris Technologies secures German clearance to expand PARADIGM heart valve trial
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Purchases $1,957,950.10 in Stock
Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Buys $1,838,834.12 in Stock
Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Buys $4,869,897.05 in Stock
Anteris Technologies appoints Brent Moen as chief financial officer
BlackRock Inc. Acquires Shares of 5,771,213 Anteris Technologies Global Corp. $AVR
Anteris to Present at September Healthcare Investor Conferences
ADAR1 Capital Management LLC Acquires New Position in Anteris Technologies Global Corp. $AVR
Assenagon Asset Management S.A. Invests $6.35 Million in Anteris Technologies Global Corp. $AVR
Anteris Technologies Announces Results for the Second Quarter of 2026
Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Sells 174,721 Shares
Pennon returns to profit after water bill hikes
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push
Anteris Announces Results for the First Quarter of 2026
Anteris Announces Results for the First Quarter of 2026
Whirlpool cuts forecast, suspends dividend as Iran war hammers demand